Cytoskeletal tumor suppressors that block oncogenic RAS signaling.
Several distinct peptides or drugs that block the Rho family GTPases-mediated pathways were found to suppress RAS-induced malignant phenotype. They include (1) C3 enzyme that selectively inactivates Rho, (2) ACK42, a peptide that blocks the interaction of CDC42 with its effectors such as ACKs, (3) PAK18, a peptide that blocks the activation of PAK and membrane ruffling, and (4) actin-binding drugs, chaetoglobosin K (CK) and MKT-077, that block membrane ruffling by capping and bundling actin filaments, respectively.
Maruta
H
H
Ludwig Institute for Cancer Research, Melbourne, Australia. hiroshi.maruta@ludwig.edu.au
He
H
H
Tikoo
A
A
Nur-e-Kamal
M
M
D000595:Amino Acid Sequence; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003572:Cytochalasins / Q000494:pharmacology; D003598:Cytoskeletal Proteins / Q000235:genetics*; D016147:Genes, Tumor Suppressor; D026121:Indole Alkaloids; D007211:Indoles / Q000494:pharmacology; D008969:Molecular Sequence Data; D015689:Oncogene Protein p21(ras) / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction
D015853:Cysteine Proteinase Inhibitors; D003572:Cytochalasins; D003598:Cytoskeletal Proteins; D026121:Indole Alkaloids; D007211:Indoles; C402747:N1445; C019290:chaetoglobosins; D015689:Oncogene Protein p21(ras)